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LETTER TO THE EDITOR Open Access
Systematic analysis of overall survival and
interactions between tumor mutations and
drug treatment
Francesco Gatto and Jens Nielsen*
Abstract
Background: Few exceptional responses in cancer treatment were attributed to a genetic predisposition of
the tumor.
Methods: We analyzed a cohort of 3105 patients from 12 different cancer types and systematically sought
the existence of a correlation between overall survival and the interaction of 21 antineoplastic treatments
with 6 tumor mutations.
Results: We identified a single significant correlation resulting in increased overall survival from temozolomide in
lower-grade glioma with IDH1 R132H mutations. The trend could not be attributed to either the treatment or the
mutation alone. Univariate and multivariate Cox regression demonstrated that this interaction stood as an independent
prognostic predictor of survival.
Conclusion: Our results suggest infrequent instances of exceptional responses ascribable to tumor genomics
yet corroborate the existence of an interaction of temozolomide with IDH1 mutations in
lower-grade glioma.
Keywords: Cancer genomics, Exceptional response, Large-scale data analysis, Systems biology, Lower-grade
glioma
Findings
The cancer genome can elicit sensitivity to certain
drugs not specifically designed to target the underlying
genetic aberrations. To this end, genomic markers of
drug sensitivity have been systematically assessed in
cancer cell lines [1, 2]. Ideally, these markers can iden-
tify patients who may better benefit from a certain anti-
neoplastic drug [3, 4]. In contrast to the increasing
availability of data about genomics of drug sensitivity in
vitro [5], the association with improved patient survival
is so far limited to few clinical cases, e.g., exceptional
responses to everolimus in bladder cancers with TSC1
mutations [6].
Here, we sought to systematically assess if the
chances of overall survival in patients with a certain
cancer type and treated with a given antineoplastic
drug correlate with the presence of a certain genetic
mutation in the tumor. The examined cohort com-
prised 3105 patients, spanning 12 cancer types (with
81–731 samples for each cancer type). Collectively, 21
antineoplastic drugs were administered each in at
least 20 patients (median 82; IQR 29–150). Six
cancer-associated mutations were detected in at least
20 patients in this cohort: V600E in BRAF (n = 29),
R132H in IDH1 (n = 108), G12V in KRAS (n = 49),
H1047R in PIK3CA (n = 89), R175H in TP53 (n = 45),
and V777 deletion in ZFHX3 (n = 22). After binning
samples by cancer type, out of 1512 potential associa-
tions, 9 associations between overall survival, drug
treatment, and tumor mutation had sufficient sample
size for each covariate and were hereby tested. The
hazard ratio (HR) for each interaction between drug
treatment and tumor mutation in a cancer type was
estimated in a multivariate analysis using a nested
Cox proportional hazard regression model. We
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adopted a likelihood ratio test to test whether there is
a significant effect of the interaction on overall sur-
vival on top of the tumor mutation and administered
drug alone (Additional file 1: Table S1).
We observed a significant effect only in one scenario,
the interaction between temozolomide (TMZ) and
R132H mutations in IDH1 on the overall survival of
lower-grade glioma (LGG) (likelihood ratio test p =
0.026). This test suggests that the correlation with sur-
vival is specific to the interaction between TMZ and
R132H mutations in IDH1 and not associated with the
drug treatment or the mutation per se, as demonstrated
by the Kaplan-Meier curves generated for patients
stratified upon these features (log-rank test p = 0.047,
Fig. 1). The median overall survival for patients with
the interaction was 95 months (95 % CI, 63—N.E.) and
for patients without the interaction was 62 months
(95 % CI, 49–87).
We detected a significant prognostic value for the
interaction using a univariate Cox proportional hazard
regression model (p = 0.016, Table 1). However, the
interaction violated the proportional hazard assumption
and showed a time-dependent effect. The univariate ana-
lysis was also run on validated prognostic factors in
LGG [7] and additional clinical features (Table 1). A
multivariate analysis based on significant factors from
the univariate analysis and including a time-dependent
effect for the interaction revealed an independent
positive correlation between the interaction and over-
all survival (HR 0.09, 95 % CI 0.01–0.58, p = 0.012),
which tends to diminish over time (Additional file 1:
Figure S1).
In conclusion, we identified one genomic marker of
drug sensitivity that was associated with better survival in
patients, in contrast to patients treated with the same drug
but with no detected mutation or vice versa. Indeed, mu-
tations in IDH1 were previously implicated with good
prognosis in brain tumors treated with TMZ [8, 9]. Our
results independently validate these findings and further
extend the reach of this correlation beyond some previous
limitations [10]. First and foremost, the cohort size
allowed discerning that an increase in patient survival was
exquisitely associated with the interaction between IDH1
mutations and TMZ, suggestive of a synergy between
Fig. 1 Kaplan-Meier survival plots for patients with or without an interaction between temozolomide and R132H mutations in IDH1 in
lower-grade glioma
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treatment and tumor genomics. Second, it specifically cor-
related with R132H mutations. Finally, we recovered a
negative time-dependent effect of the interaction, which is
reminiscent of emergence of drug resistance and in line
with the genetic evolution of lower-grade glioma attrib-
uted to TMZ treatment [11].
Table 1 Hazard ratio (HR) for clinical factors in the overall survival of lower-grade glioma
Factors N
[n death]
HR Univariate Multivariate
95 % CI p HR 95 % CI p
Age 261 1.07 1.05–1.09 5e−10 1.07 1.05–1.09 6e−9
Gender
Female 117 [30] 1
Male 144 [33] 0.88 0.54–1.45 0.620
Temozolomide
No 41 [24] 1
Yes 220 [39] 0.80 0.47–1.35 0.398
R132H in IDH1
Undetected 166 [45] 1
Detected 95 [18] 0.74 0.43–1.29 0.292
Interaction drug-mutation
Absent 181 [57] 1 1
Present 80 [6] 0.35 0.15–0.83 0.016 0.09 0.01–0.58 0.012
Histology
Astrocytoma 107 [27] 1
Oligoastrocytoma/
oligodendroglioma
154 [36] 0.67 0.40–1.10 0.112
Tumor grade
Grade II 77 [18] 1 1
Grade III 184 [45] 2.06 1.18–3.61 0.011 1.52 0.85–2.71 0.159
Laterality
N.A. 1
Left 131 [28] 1
Midline 5 [1] 0.34 0.04–2.64 0.304
Right 123 [33] 0.82 0.49–1.37 0.443
Tumor site
N.A./other 3 1
Supratentorial, frontal lobe 160 [36] 1
Supratentorial, occipital lobe 5 [1] 0.71 0.10–5.20 0.736
Supratentorial, parietal lobe 23 [4] 0.84 0.30–2.38 0.748
Supratentorial, temporal lobe 70 [21] 1.86 1.08–3.22 0.026 1.22 0.70–2.11 0.481
Symptoms at diagnosis
N.A./other 19
Headaches 62 [18] 1
Mental status changes 22 [8] 1.84 0.80–4.27 0.153
Motor/movement changes 22 [6] 1.20 0.47–3.06 0.698
Seizures 119 [23] 0.58 0.31–1.08 0.087
Sensory changes 11 [2] 1.07 0.24–4.66 0.929
Visual changes 6 [2] 0.69 0.16–2.98 0.617
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